STAT

Those CRISPR’d human embryos? We got it right, scientists insist, rejecting criticism

The brawl over a paper reporting the use of CRISPR to edit out a disease-causing gene from human embryos has been largely resolved, with one critic saying, "I've come to…

When scientists announced last summer that they had used CRISPR to eliminate a disease-causing gene in human embryos, critics immediately erupted with, “You didn’t!” Some meant it in the sense of, omigod, how could you take this step toward designer babies? Others meant, no, your experiment didn’t do what you claimed it did.

The ethical debate about designer babies will probably last longer than the West Antarctic Ice Sheet, but the scientific brawl about the study’s claims has been mostly resolved. In new papers published Wednesday, two groups of scientists detail why they think the researchers, Shoukhrat Mitalipov of Oregon Health and Science University and his colleagues reject the criticism, reporting that they re-tested the embryos — and got the same results.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks